Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $26.00 per share for total gross proceeds of $182.0 million. Health Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. Health Catalyst’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “HCAT” on July 25, 2019. The offering is expected to close on July 29, 2019, subject to customary closing conditions.
Goldman Sachs & Co. LLC, J.P. Morgan, and William Blair are acting as joint book-running managers for the offering as representatives of the underwriters. Piper Jaffray, Evercore ISI, and SVB Leerink are acting as passive book-running managers for the offering. SunTrust Robinson Humphrey is acting as co-manager for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, tele
